Cramer says Apple and Eli Lilly still have room to run after post-earnings rallies
Jim Cramer expressed optimism about Apple and Eli Lilly, stating they still have growth potential despite recent post-earnings rallies. He believes strong fundamentals and innovation will continue to drive their stock performance. Cramer emphasized confidence in both companies' long-term strategies.
- ▪Jim Cramer highlighted Apple's continued innovation as a key growth driver.
- ▪He noted Eli Lilly's strong pipeline and demand for its pharmaceutical products.
- ▪Cramer argued that both stocks are not overvalued despite recent gains.
- ▪He advised investors to hold or consider adding positions in Apple and Eli Lilly.
- ▪The comments were made on CNBC's 'Mad Money' program.
Opening excerpt (first ~120 words) tap to expand
Subscribe to CNBC PROSubscribe to Investing ClubLicensing & ReprintsCNBC CouncilsSelect Personal FinanceJoin the CNBC PanelClosed CaptioningDigital ProductsNews ReleasesInternshipsCorrectionsAbout CNBCSite MapPodcastsCareersHelpContactNews TipsGot a confidential news tip? We want to hear from you.Get In TouchCNBC NewslettersSign up for free newsletters and get more CNBC delivered to your inboxSign Up NowGet this delivered to your inbox, and more info about our products and services.Advertise With UsPlease Contact UsAd ChoicesPrivacy PolicyYour Privacy ChoicesCA NoticeTerms of Service© 2026 Versant Media, LLC. All Rights Reserved. A Versant Media Company. Data is a real-time snapshot *Data is delayed at least 15 minutes.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at CNBC — Top.
Discussion
0 commentsMore from CNBC — Top
